To assess whether late introduction of a specific COX-2 inhibitor (Meloxicam) can treat and/or prevent the progression of tumors in the stomach of rats submitted to duodenogastric reflux. 
Introduction
Several studies indicate that COX-2 expression is a relatively early event during stomach carcinogenesis process 1 .
The results of COX expression analysis have shown that COX-2 is increased in gastric cancer, but not in normal mucosa suggesting that this enzyme plays an important role in the gastric carcinogenesis 2 . Some studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) are associated with reduced incidence of gastric cancer 3, 4 . The inhibitory effect of NSAIDs on the Cox action, and consequently the decrease in the production of prostaglandins is identified as the main chemopreventive effect of these drugs. Prostaglandins act as promoter of carcinogenesis because the reduction of their levels is associated to a decrease in the carcinogenesis and instead sustained increase is associated with a facilitating effect for the development of tumors 5 .
Recently two studies performed in rats submitted to a surgical procedure of duodenogastric reflux (DGR) have shown that oral administration of specific COX-2 inhibitors, Meloxicam in the first 6 and Celecoxib in the latter 7 can prevent the development of gastric proliferative lesions in gastric mucosa. In these studies, the oral intake of specifics COX-2 inhibitors started as soon as DGR was induced and; therefore, still without established proliferative lesions at the gastric mucosa. However, it is poorly investigated if oral intake of Meloxicam could be a preventive drug when gastric proliferative lesions were already present. Such study would have clinical relevance since thousands of patients underwent to a surgical treatment for peptic ulcers can potentially have a greater or lesser degree of DGR. It has also been shown that some patients underwent to partial gastrectomies for treatment of peptic ulcer disease show a higher risk for of development of gastric stump cancer than those non-gastrectomized. This risk is correlated with the intensity of DGR, since cancer incidence is higher in patients underwent to a Billroth II type gastrectomies where DGR would be more intense. Also is known through experimental studies that induction of DGR alone is enough for the development of gastric cancer in the rat stomach. Therefore, to test if late administration of a specific COX-2 inhibitor (Meloxicam) can treat and/or prevent the progression of gastric tumors in rats submitted to duodenogastric reflux procedure we designed the present study.
Methods
The study follows the Council for International
Organization of Medical Sciences (CIOMS) ethical code for animal experimentation. A series of 75 male Wistar rats weighing 150 g were fed a standard rat chow and tap water ad libitum.
The animals were kept under standard conditions in a controlled room kept at a 22 + 2 0 C and a 12/12 h light/dark cycle. After initial acclimation, they were submitted to the surgical procedure to obtain the duodenogastric reflux through the pylorus (DGR).
After intra-peritoneal anesthesia with sodium pentobarbital (30 mg/kg body wt) a midline laparotomy was performed. Then, 1 cm anastomosis was constructed between a jejunal segment (4 cm ahead to the Treitz's ligament) and stomach anterior wall. At sequence, the jejunum was divided and both cut ends had been closed 1 cm before the gastrojejunal anastomosis, in order to allow the flow of the duodenal content to the stomach ( Figure 1 ). After DGR surgery, the animals had access only to tap water; solid food was allowed after 24h. Body weight was measured weekly.
At the necropsy, abdominal cavity was examined for the presence of ascites, fistulae, prominent lymphatic nodules and carcinomatosis. The stomach was removed, opened along the great
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The specims were spread on a cork plate on the serosal surface and fixed by immersion in 10% buffered formalin. Each stomach was sectioned into successive longitudinal cuts including the oxyntic and the pyloric mucosa. The gastrojejunal portion was submitted to successive transverse cuts including the oxyntic mucosa and the jejunal loop. The specimens were embedded in paraffin and stained with hematoxylin/eosin. All histopathological analyses were performed by the same investigator who was unaware of the experimental group to which the specimen belonged.
For statistical analysis was adjusted a generalized linear model assuming a binomial distribution with LOGIT link function.
Differences were considered significant when the p value was < 0.05. at the gastrojejunal stoma and none at the pyloric mucosa. In DGR54MLX we found polypoid lesions at the gastrojejunal stoma in five out of 12 rats (41.6%) and at the pyloric mucosa 1 out of 12 (8.3%). No remarkable macroscopic alterations were found at the squamous portion of gastric mucosa or into the abdominal cavity (Table 1) . 
Results

Macroscopy
Histology
Data for the distribution of the histological lesions at the pyloric mucosa and at the gastrojejunal anastomosis are shown in Table 2 . We found two types of proliferative lesions: Adenomatous When we induced the reflux of duodenal contents through the pylorus, the compounds of duodenal contents cause a great injury to the gastric mucosa and therefore may promote a huge oxidative stress (OS), which is considered a potent inducer of the transcription growth factor epithelium (VEGF), which interacts closely with the COX-2 in the neoangiogenesis which supporting the carcinogenesis. OS is a mutagen capable of damaging cellular DNA, while proteins responsible for its repair, and therefore, the proper inflammatory process may potentially act as initiator cancer through oxygen free radicals and nitric oxide generation 15, 16 .
Our results have demonstrated that late introduction of specific COX-2 inhibitor (Meloxicam) did not treat and was not able to prevent the progression of proliferative lesions at the gastric mucosa submitted to reflux of duodenal contents. We found no statistical difference among the groups DGR54 and DGR54MLX in regarding to Adenomatous Hyperplasia or Adenocarcinoma. As COX-2 expression is a relatively early event during carcinogenesis into the stomach, is possible to suggest that when Meloxicam was administered the inhibition of COX-2 probably was no longer an important step to interrupt the carcinogenesis process. The fact that one adenocarcinoma was diagnosed in one animal of DGR36 shows that carcinogenesis process was in an advanced stage when the drug administration was started. Possibly the lesions already had reached a point of no return of the carcinogenesis process, characterized by autonomy, maintenance or even stimulation of this process mediated by the effect of unrelated promoters of carcinogenesis not linked with the primary cause of injuries. Another possibility to explain the negative result could be that Meloxicam dosage was insufficient to block COX-2 in these experimental conditions. More studies need to be done for clarify the potential use of COX-2 specific inhibitors against carcinogenesis process.
Conclusion
Late introduction of specific COX-2 inhibitor (Meloxicam) did not treat and was not able to prevent the progression of tumoral lesions induced by duodenogastric reflux in the rat stomachs.
